The US District Court for the Southern District of New York upheld 2 patents covering the opioid agonist Opana® ER (oxymorphone), according to an announcement made last week by the manufacturer, Endo International. The decision protects the product against generic competition until 2023. In 2012, Endo had filed a lawsuit against Actavis, which has since merged with Allergan, after the latter launched a generic version of a noncrush-resistant formulation of Opana. Based on the ruling, Endo voiced the expectation that this generic version would be removed from the market and that other generic versions that were approved but not yet brought to market would not be made available until after patent expiry.
Opana ER is indicated for the management of severe pain requiring daily around the clock opioid therapy, and for which alternative treatments are inadequate. The product generated revenues of some $90 million for the 6 months ending June 30, 2015, a figure down 11% from the year ago period. Investment researcher Zacks International states that the court ruling and resultant removal of generic competition may improve revenue performance going forward.
Read more about the ruling here.